Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
KING OF PRUSSIA, Pa., April 26, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the 42nd Annual Healthcare Conference hosted by Deutsche Bank Securities on Wednesday, May 3, 2017, at 2:50 p.m. EDT in Boston.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection), currently in Phase 3 development for the management of moderate-to-severe acute pain. Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Vice President, Corporate Strategy & Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
